BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 32959502)

  • 1. Plasma D-dimer concentrations predicting stroke risk and rivaroxaban benefit in patients with heart failure and sinus rhythm: an analysis from the COMMANDER-HF trial.
    Ferreira JP; Lam CSP; Anker SD; Mehra MR; van Veldhuisen DJ; Byra WM; La Police DA; Cleland JGF; Greenberg B; Zannad F
    Eur J Heart Fail; 2021 Apr; 23(4):648-656. PubMed ID: 32959502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Risk of Stroke in Patients With Worsening Heart Failure, Reduced Ejection Fraction, Coronary Heart Disease and Sinus Rhythm: Risk Prediction Score Analysis From the COMMANDER-HF Trial.
    Monzo L; Girerd N; Ferreira JP; Lamiral Z; Anker SD; Cleland JGF; Kondo T; McMurray JJV; Lam CSP; Mehra MR; Veldhuisen DJV; Greenberg B; Zannad F
    J Card Fail; 2024 Apr; 30(4):618-623. PubMed ID: 38122924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
    Greenberg B; Neaton JD; Anker SD; Byra WM; Cleland JGF; Deng H; Fu M; La Police DA; Lam CSP; Mehra MR; Nessel CC; Spiro TE; van Veldhuisen DJ; Vanden Boom CM; Zannad F
    JAMA Cardiol; 2019 Jun; 4(6):515-523. PubMed ID: 31017637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial: Insights From COMMANDER HF.
    Cunningham JW; Ferreira JP; Deng H; Anker SD; Byra WM; Cleland JGF; Gheorghiade M; Lam CSP; La Police D; Mehra MR; Neaton JD; Spiro TE; van Veldhuisen DJ; Greenberg B; Zannad F
    JACC Heart Fail; 2020 May; 8(5):359-368. PubMed ID: 32171760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial.
    Mehra MR; Vaduganathan M; Fu M; Ferreira JP; Anker SD; Cleland JGF; Lam CSP; van Veldhuisen DJ; Byra WM; Spiro TE; Deng H; Zannad F; Greenberg B
    Eur Heart J; 2019 Nov; 40(44):3593-3602. PubMed ID: 31461239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease.
    Zannad F; Anker SD; Byra WM; Cleland JGF; Fu M; Gheorghiade M; Lam CSP; Mehra MR; Neaton JD; Nessel CC; Spiro TE; van Veldhuisen DJ; Greenberg B;
    N Engl J Med; 2018 Oct; 379(14):1332-1342. PubMed ID: 30146935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial.
    Zannad F; Greenberg B; Cleland JG; Gheorghiade M; van Veldhuisen DJ; Mehra MR; Anker SD; Byra WM; Fu M; Mills RM
    Eur J Heart Fail; 2015 Jul; 17(7):735-42. PubMed ID: 25919061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New-onset atrial fibrillation in patients with worsening heart failure and coronary artery disease: an analysis from the COMMANDER-HF trial.
    Ferreira JP; Cleland JG; Lam CSP; Anker SD; Mehra MR; van Veldhuisen DJ; Byra WM; LaPolice DA; Greenberg B; Zannad F
    Clin Res Cardiol; 2022 Jan; 111(1):50-59. PubMed ID: 34128083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease.
    Branch KR; Probstfield JL; Eikelboom JW; Bosch J; Maggioni AP; Cheng RK; Bhatt DL; Avezum A; Fox KAA; Connolly SJ; Shestakovska O; Yusuf S
    Circulation; 2019 Aug; 140(7):529-537. PubMed ID: 31163978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular effects of rivaroxaban in heart failure patients with sinus rhythm and coronary disease with and without diabetes: a retrospective international cohort study from COMMANDER-HF.
    Sharma A; Caldeira D; Razaghizad A; Pinto FJ; van Veldhuisen DJ; Mehra MR; Lam CSP; Cleland J; Anker SD; Greenberg B; Ferreira JP; Zannad F
    BMJ Open; 2023 Aug; 13(8):e068865. PubMed ID: 37567750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. D-Dimer Levels and Effect of Rivaroxaban on Those Levels and Outcomes in Patients With Acute Coronary Syndrome (An ATLAS ACS-TIMI 46 Trial Substudy).
    AlKhalfan F; Kerneis M; Nafee T; Yee MK; Chi G; Plotnikov A; Braunwald E; Gibson CM
    Am J Cardiol; 2018 Nov; 122(9):1459-1464. PubMed ID: 30217378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. D-Dimer Predicts Long-Term Cause-Specific Mortality, Cardiovascular Events, and Cancer in Patients With Stable Coronary Heart Disease: LIPID Study.
    Simes J; Robledo KP; White HD; Espinoza D; Stewart RA; Sullivan DR; Zeller T; Hague W; Nestel PJ; Glasziou PP; Keech AC; Elliott J; Blankenberg S; Tonkin AM;
    Circulation; 2018 Aug; 138(7):712-723. PubMed ID: 29367425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and heart failure.
    Martinez BK; Bunz TJ; Eriksson D; Meinecke AK; Sood NA; Coleman CI
    ESC Heart Fail; 2019 Feb; 6(1):10-15. PubMed ID: 30299591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticoagulation Therapy and NOACs in Heart Failure.
    Thomas I; EncisoSilva J; Schlueter M; Greenberg B
    Handb Exp Pharmacol; 2017; 243():515-535. PubMed ID: 28233177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serial heart rate measurement and mortality after acute heart failure.
    Ancion A; Tridetti J; Nguyen Trung ML; Oury C; Lancellotti P
    ESC Heart Fail; 2020 Feb; 7(1):103-106. PubMed ID: 31800172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased d-dimer levels predict cardiovascular mortality in patients with systolic heart failure.
    Zorlu A; Yilmaz MB; Yucel H; Bektasoglu G; Refiker Ege M; Tandogan I
    J Thromb Thrombolysis; 2012 May; 33(4):322-8. PubMed ID: 21901368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin D deficiency in patients with diastolic dysfunction or heart failure with preserved ejection fraction.
    Nolte K; Herrmann-Lingen C; Platschek L; Holzendorf V; Pilz S; Tomaschitz A; Düngen HD; Angermann CE; Hasenfuß G; Pieske B; Wachter R; Edelmann F
    ESC Heart Fail; 2019 Apr; 6(2):262-270. PubMed ID: 30784226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma fibrinogen and fibrin D-dimer in patients with atrial fibrillation: effects of cardioversion to sinus rhythm.
    Lip GY; Rumley A; Dunn FG; Lowe GD
    Int J Cardiol; 1995 Oct; 51(3):245-51. PubMed ID: 8586473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment.
    Lip GY; Lowe GD; Rumley A; Dunn FG
    Br Heart J; 1995 Jun; 73(6):527-33. PubMed ID: 7626351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated Plasma D-Dimer Level Is Associated With Short-Term Risk of Ischemic Stroke in Patients With Acute Heart Failure.
    Hamatani Y; Nagai T; Nakai M; Nishimura K; Honda Y; Nakano H; Honda S; Iwakami N; Sugano Y; Asaumi Y; Aiba T; Noguchi T; Kusano K; Toyoda K; Yasuda S; Yokoyama H; Ogawa H; Anzai T;
    Stroke; 2018 Jul; 49(7):1737-1740. PubMed ID: 29880555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.